Skip to main content
Pentixapharm Holding AG logo

Pentixapharm Holding AG — Investor Relations & Filings

Ticker · PTP ISIN · DE000A40AEG0 LEI · 3912005VBOVXNDXEQZ36 F Manufacturing
Open in API
Filings indexed 62 across all filing types
Latest filing 2025-07-24 Report Publication Anno…
Country DE Germany
Listing F PTP

About Pentixapharm Holding AG

https://www.pentixapharm.com/

Pentixapharm Holding AG is a clinical-stage company focused on developing first-in-class radiopharmaceuticals. The company's research and development centers on CXCR4 ligand-based compounds for diagnostic and therapeutic applications. Its clinical pipeline features two drug candidates that are ready for Phase III trials. One of its lead assets is the radiodiagnostic candidate 68Ga-PentixaFor, which is being prepared for a Phase 3 study for applications in hypertension. The company's core CXCR4 compound has been extensively studied, administered to over 2,000 patients, and is the subject of more than 150 scientific publications.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2025
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2015 characters) from Pentixapharm Holding AG regarding the upcoming publication of their half-year/Q2 financial reports. It explicitly states the date of disclosure and provides a link to where the reports will be available. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-07-24 English
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
Report Publication Announcement Classification · 100% confidence The document is a short notification (772 characters) informing stakeholders that the company's half-year financial report is available for download on their website. It does not contain the financial report itself, but rather acts as a formal announcement of its publication. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-07-24 German
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 1,000 characters) that informs shareholders about the availability of the company's half-year financial report. It provides a link to the website where the report can be accessed and specifies the publication date. According to the 'Menu vs Meal' rule, since this is an announcement of a report's availability rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-07-24 German
Jahresabschluss zum Geschäftsjahr vom 18.03.2024 bis zum 31.12.2024
Audit Report / Information Classification · 100% confidence The document is a formal 'Bestätigungsvermerk' (Audit Opinion/Report) issued by an independent auditor for Pentixapharm Holding AG. It details the audit of the annual financial statements (Jahresabschluss) and the management report (Lagebericht) for the fiscal year ending December 31, 2024. It includes sections on audit opinions, key audit matters (Werthaltigkeit der Anteile), and the responsibilities of the auditor and management. This is a standalone audit report document, not a full annual report or a simple announcement. FY 2024
2025-06-11 German
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as an "Ad-hoc announcement pursuant to Art. 17 MAR / Section 15 WpHG" and discloses "inside information." This format is characteristic of mandatory regulatory disclosures in the EU regarding material non-public information. The content discusses a strategic shift in clinical development, discontinuation of a trial, and future plans. This type of material, non-financial, strategic update that is not a full financial report (10-K, IR) or a standard earnings release (ER) often falls under general regulatory announcements. Since it is a mandatory disclosure of material information under MAR (Market Abuse Regulation), and it doesn't fit perfectly into specific categories like DIRS, DIV, or CAP, the most appropriate general regulatory category is RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes.
2025-05-27 English
Konzernabschluss zum Geschäftsjahr vom 18.03.2024 bis zum 31.12.2024
Audit Report / Information Classification · 100% confidence The document is a 'Bestätigungsvermerk' (Audit Opinion) issued by an independent auditor for Pentixapharm Holding AG. It covers the audit of the consolidated financial statements and the management report for the short fiscal year 2024. It details the audit scope, key audit matters (such as the spin-off from Eckert & Ziegler SE and the valuation of development costs), and the auditor's opinion. This is a standalone audit report document, not the full annual report itself, and it does not fit the criteria for an announcement (RPA) or other categories. FY 2024
2025-05-14 German

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.